Chronic agomelatine treatment corrects the anormalities in the circadian rhythm of motor activity andb sleep/wake cycle induced by prenatal restraint stress in adult rats

International Journal of Neuropsychopharmacology

Volumn 16, Issue 2, 2013, Pages 323-338

  Mairesse, Jerome ^a,b   Silletti, Viviana ^b   Laloux, Charlotte ^b   Zuena, Anna Rita ^b   Giovine, Angela ^a,b   Consolazione, Michol ^b   Van Camp, Gilles ^a   Malagodi, Marithe ^a   Gaetani, Silvana ^b   Cianci, Silvia ^b   Catalani, Assia ^b   Mennuni, Gioacchino ^c   Mazzetta, Alessandro ^b   Van Reeth, Olivier ^c,d   Gabriel, Cecilia ^e   Mocaër, Elisabeth ^e   Nicoletti, Ferdinando ^a,f   Morley Fletcher, Sara ^a   MacCari, Stefania ^a  

^a UNIV LILLE   (France)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^e INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^f IRCCS NEUROMED   (Italy)

Author keywords

Agomelatine; hippocampus; motor activity; prenatal restraint stress; sleep

Indexed keywords

AGOMELATINE; PROTEIN C FOS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCADIAN RHYTHM; CIRCADIAN RHYTHM SLEEP DISORDER; CONTROLLED STUDY; DEPRESSION; FEMALE; IMMOBILIZATION STRESS; LIGHT DARK CYCLE; LONG TERM CARE; MOTOR ACTIVITY; NONHUMAN; PRENATAL STRESS; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; RAT; REM SLEEP; SLEEP WAKING CYCLE; SLOW WAVE SLEEP;

ACETAMIDES; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; AROUSAL; AUTORADIOGRAPHY; CHRONOBIOLOGY DISORDERS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; FEMALE; HIPPOCAMPUS; HYPNOTICS AND SEDATIVES; MALE; MOVEMENT DISORDERS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MELATONIN; RESTRAINT, PHYSICAL; SLEEP DISORDERS; THIOPHENES;

EID: 84875915508     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711001970     Document Type: Article

References (57)

1. Akiskal HS, McKinney WT (1975). Overview of recent research in depression. Integration of ten conceptual models into a comprehensive clinical frame. Archives of General Psychiatry 32, 285-305.
2. Armstrong SM, McNulty OM, Guardiola-Lemaitre B, Redman JR (1993). Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacology Biochemistry and Behavior 46, 45-49.
3. Audinot V, Mailliet F, Lahaye-Brasseur C, Bonnaud A, et al. (2003). New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn-Schmiedeberg's Archives of Pharmacology 367, 553-561.
4. Berton O, Nestler EJ (2006). New approaches to antidepressant drug discovery: beyond monoamines. Nature Reviews Neuroscience 7, 137-151.
5. Best J, Diniz Behn C, Poe GR, Booth V (2007). Neuronal models for sleep-wake regulation and synaptic reorganization in the sleeping hippocampus. Journal of Biological Rhythms 22, 220-232.
6. Dagyte G, Trentani A, Postema F, Luiten PG, et al. (2010). The novel antidepressant agomelatine normalizes hippocampal neuronal activity and promotes neurogenesis in chronically stressed rats. CNS Neuroscience and Therapeutics 16, 195-207.
7. Darnaudery M, Perez-Martin M, Belizaire G, Maccari S, et al. (2006). Insulin-like growth factor 1 reduces age-related disorders induced by prenatal stress in female rats. Neurobiology of Aging 27, 119-127.
8. de Bodinat C, Guardiola-Lemaitre B, Mocaër E, Renard P, et al. (2010). Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nature Reviews Drug Discovery 9, 628-642.
9. Descamps A, Rousset C, Millan MJ, Spedding M, et al. (2009). Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture. Psychopharmacology (Berlin) 205, 93-106.
10. Dugovic C, Maccari S, Weibel L, Turek FW, et al. (1999). High corticosterone levels in prenatally stressed rats predict persistent paradoxical sleep alterations. Journal of Neuroscience 19, 8656-8664.
11. Duman CH, Schlesinger L, Kodama M, Russell DS, et al. (2007). A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biological Psychiatry 61, 661-670.
12. Forsling ML (2000). Diurnal rhythms in neurohypophysial function. Experimental Physiology 85, 179-186.
13. Fountoulakis KN (2010). Disruption of biological rhythms as a core problem and therapeutic target in mood disorders: the emerging concept of 'rhythm regulators'. Annals of General Psychiatry 9, 3.
14. Gaetani S, Fu J, Cassano T, Dipasquale P, et al. (2010). The fat-induced satiety factor oleoylethanolamide suppresses feeding through central release of oxytocin. Journal of Neuroscience 30, 8096-8101.
15. Gerstner JR, Yin JC (2010). Circadian rhythms and memory formation. Nature Reviews Neuroscience 11, 577-588.
16. Halford JC, Harrold JA, Boyland EJ, Lawton CL, et al. (2007). Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 67, 27-55.
17. Hegde P, Singh K, Chaplot S, Shankaranarayana Rao BS, et al. (2008). Stress-induced changes in sleep and associated neuronal activity in rat hippocampus and amygdala. Neuroscience 153, 20-30.
18. Grassi-Zucconi G, Semprevivo M, Mocaer E, Kristensson K, et al. (1996). Melatonin and its new agonist S-20098 restore synchronized sleep fragmented by experimental trypanosome infection in the rat. Brain Research Bulletin 39, 63-68.
19. Karlsson KA, Blumberg MS (2003). Hippocampal theta in the newborn rat is revealed under conditions that promote REM sleep. Journal of Neuroscience 23, 1114-1118.
20. Kasper S, Hajak G, Wulff K, Hoogendijk WJ, et al. (2010). Efficacy of the novel antidepressant agomelatine on the circadian rest-Activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. Journal of Clinical Psychiatry 71, 109-120.
21. Kennaway DJ (2010). Clock genes at the heart of depression. Journal of Psychopharmacology 24, 5-14.
22. Kopp C, Vogel E, Rettori MC, Delagrange P, et al. (1999). Antagonistic effects of S 22153, a new mt1 and MT2 receptor ligand, on the neophobia-reducing properties of melatonin in BALB/c mice. Pharmacology Biochemistry and Behavior 64, 131-136.
23. Krishnan V, Nestler EJ (2010). Linking molecules to mood: new insight into the biology of depression. American Journal of Psychiatry 167, 1305-1320.
24. Lemaire V, Koehl M, Le Moal M, Abrous DN (2000). Prenatal stress produces learning deficits associated with an inhibition of neurogenesis in the hippocampus. Proceedings of the National Academy of Sciences USA 97, 11032-11037.
25. Lopes MC, Quera-Salva MA, Guilleminault C (2007). Non-REM sleep instability in patients with major depressive disorder: subjective improvement and improvement of non-REM sleep instability with treatment (agomelatine). Sleep Medicine 9, 33-41.
26. McClung CA (2007). Circadian genes, rhythms and the biology of mood disorders. Pharmacology and Therapeutics 114, 222-232.
27. Maccari S, Piazza PV, Kabbaj M, Barbazanges A, et al. (1995). Adoption reverses the long-term impairment in glucocorticoid feedback induced by prenatal stress. Journal of Neuroscience 15, 110-116.
28. Mairesse J, Viltart O, Salomé N, Giuliani A, et al. (2007). Prenatal stress alters the negative correlation between neuronal activation in limbic regions and behavioral responses in rats exposed to high and low anxiogenic environments. Psychoneuroendocrinology 32, 765-776.
29. Martinet L, Guardiola-Lemaitre B, Mocaer E (1996). Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent. Pharmacology Biochemistry and Behavior 54, 713-718.
30. Millan MJ (2006). Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacology and Therapeutics 110, 135-370.
31. Millan MJ, Gobert A, Lejeune F, Dekeyne A, et al. (2003). The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. Journal of Pharmacology and Experimental Therapeutics 306, 954-964.
32. Morley-Fletcher S, Mairesse J, Soumier A, Banasr M, et al. (2011). Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats. Psychopharmacology 217, 301-313.
33. Morley-Fletcher S, Rea M, Maccari S, Laviola G (2003). Environmental enrichment during adolescence reverses the effects of prenatal stress on play behaviour and HPA axis reactivity in rats. European Journal of Neuroscience 18, 3367-3374.
34. Nestler EJ, Hyman SE (2010). Animal models of neuropsychiatric disorders. Nature Neuroscience 13, 1161-1169.
35. Pandi-Perumal SR, Moscovitch A, Srinivasan V, Spence DW, et al. (2009). Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine. Progress in Neurobiology 88, 264-271.
36. Papp M, Gruca P, Boyer PA, Mocaër E (2003). Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 28, 694-703.
37. Paxinos G, Watson C (2005). The Rat Brain in Stereotaxic Coordinates, 5th edn. Amsterdam: Elsevier Academic Press.
38. Pjrek E, Winkler D, Konstantinidis A, Willeit M, et al. (2007). Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology (Berlin) 190, 575-579.
39. Quera-Salva MA, Lemoine P, Guilleminault C (2010). Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients. Human Psychopharmacology 25, 222-229.
40. Quera-Salva MA, Vanier B, Laredo J, Hartley S, et al. (2007). Major depressive disorder, slepp EEG and agomelatine: an open-label study. International Journal of Neuropsychopharmacology 10, 691-696.
41. Rainer Q, Xiq L, Guilloux JP, Gabriel C, et al. (2011). Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. International Journal of Neuropsychopharmacology 8, 1-15.
42. Soumier A, Banasr M, Lortet S, Masmejean F, et al. (2009). Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology 34, 2390-2403.
43. Srinivasan V, Smits M, Spence W, Lowe AD, et al. (2006). Melatonin in mood disorders. World Journal of Biological Psychiatry 7, 138-151.
44. Staba RJ, Wilson CL, Fried I, Engel J (2002). Single neuron burst firing in the human hippocampus during sleep. Hippocampus 12, 724-734.
45. Tobler I, Jaggi K, Borbély AA (1994). Effects of melatonin and the melatonin receptor agonist S-20098 on the vigilance states, EEG spectra, and cortical temperature in the rat. Journal of Pineal Research 16, 26-32.
46. Vallee M, Mayo W, Dellu F, Le Moal M, et al. (1997). Prenatal stress induces high anxiety and postnatal handling induces low anxiety in adult offspring: correlation with stress induced corticosterone secretion. Journal of Neuroscience 17, 2626-2636.
47. van Reeth O, Mairesse J, Giovine A, Mennunni G, et al. (2007). Prenatal stress induces abnormal stress response and alters circadian rhythms of corticosterone and locomotor activity in adult rats. Program No. 501.29/KK2. Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience.
48. van Reeth O, Olivares E, Turek FW, Granjon L, et al. (1998). Resynchronisation of a diurnal rodent circadian clock accelerated by a melatonin agonist. Neuroreport 9, 1901-1905.
49. van Reeth O, Weibel L, Olivares E, Maccari S, et al. (2001). Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 280, R1582-R1591.
50. van Reeth O, Weibel L, Spiegel K, Leproult R, et al. (2000). Interactions between stress and sleep: from basic research to clinical situations. Sleep Medicine Reviews 4, 201-219.
51. Viltart O, Mairesse J, Darnaudéry M, Louvart H, et al. (2006). Prenatal stress alters Fos protein expression in hippocampus and locus coeruleus stress-related brain structures. Psychoneuroendocrinology 31, 769-780.
52. Vyazovskiy VV, Cirelli C, Pfister-Genskow M, Faraguna U, et al. (2008). Molecular and electrophysiological evidence for net synaptic potentiation in wake and depression in sleep. Nature Neuroscience 11, 200-208.
53. Weibel L, Turek FW, Mocaer E, Van Reeth O (2000). A melatonin agonist facilitates circadian resynchronization in old hamsters after abrupt shifts in the light-dark cycle. Brain Research 13, 207-211.
54. Wilson S, Argyropoulos S (2005). Antidepressants and sleep: a qualitative review of the literature. Drugs 65, 927-947.
55. Wulff K, Gatti S, Wettstein JG, Foster RG (2010). Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease. Nature Reviews Neuroscience 11, 589-599.
56. Zuena AR, Mairesse J, Casolini P, Cinque C et al. (2008). Prenatal restraint stress generates two distinct behavioural and neurochemical profiles in male and female rats. PLoS One 3, e2170.
57. Zupancic M, Guilleminault C (2006). Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 20, 981-992.